A larger pilot study of galectin-3 in those 3 patient groups in addition to the 2 patient groups in this report is being conducted to validate our initial findings, and to see if a gradient exists in galectin-3 levels across a broader (5-group) spectrum of PCa. The gene discussed is LGALS3; the disease is posterior cortical atrophy.